Back to search results

The GLASS Study: DSLT for Glaucoma

The GLASS Study is looking at whether repeating a non-invasive laser treatment called Direct Selective Laser Trabeculoplasty (DSLT) can help control eye pressure for people with early-stage glaucoma or ocular hypertension (high eye pressure). This study is the first to test DSLT in both eyes of patients who haven't used other eye pressure medications. All 48 participants will receive DSLT in both eyes. After three months, one eye will get a second DSLT treatment, while the other eye will be observed. The main goal is to see if two treatments lower eye pressure more effectively than one, potentially reducing the need for daily eye drops. You may be eligible if you are 40 or older, have a diagnosis of ocular hypertension, glaucoma suspect, or mild primary open-angle glaucoma in both eyes, and have not used eye pressure medications before.

Study design
This is an interventional study with 48 participants. It uses a paired-eye design where both eyes receive treatment, and one eye is randomly selected for a second treatment.
What's involved
You will have a screening visit, a baseline visit where both eyes receive DSLT, and a 3-month visit where one eye receives a second DSLT session.
Compensation
Not stated in the trial record.
Follow-up
Your eye pressure will be measured from baseline up to Month 3.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06963684

Glaucoma Laser Assessment of Stability and Sustainability

Recruiting
NAAges 40+InterventionalTreatment
Twin Cities Eye Consultants
~48 participants
Updated 2025-05-14 on ClinicalTrials.gov
What's tested:Dual-Treatment Direct Selective Laser Trabeculoplasty (DSLT)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean Decrease in Intraocular Pressure (IOP) from Baseline
Measured over Baseline to Month 3

Conditions

Glaucoma

Explore related trials

GlaucomaGlaucoma suspectOcular Hypertension

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • George R Wandling, MD · PRINCIPAL_INVESTIGATOR · Twin Cities Eye Consultants - Partner

Who to contact

Hannah Schoenecker
[email protected]
612-999-2020
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male and female patients aged 40 years or older
A bilateral diagnosis of ocular hypertension, glaucoma suspect, or mild primary open angle glaucoma as defined by AAO PPP
Treatment naïve with an unmedicated IOP between 21-35 mmHg, inclusive, and within +/- 3mmHg of each eye to be eligible
BCVA of 20/50 or better
The subject is able to read and understand the requirements of the study and provide written informed consent.
The subject is willing to follow study instructions, agrees to comply with all study procedures and attend all scheduled follow-up exams for 12 months after the initial treatment.

Exclusion

Unable to view scleral spur inferiorly with gonioscopy.
Congenital or developmental glaucoma, angle closure glaucoma, secondary glaucoma (e.g. exfoliative, pigmentary, etc.) pigmentary, neovascular glaucoma, closed angle glaucoma, or uveitic glaucoma.
Use of oral or ocular hypotensive medication for glaucoma.
Prior history of ocular surgery except for cataract surgery (must be ≥ 2 years prior)
Clinically significant ocular pathology, other than cataract and glaucoma, including but not limited to neovascular age-related macular degeneration, advanced dry macular degeneration, and proliferative diabetic retinopathy, etc.
Clinically significant ocular inflammation or infection within 6 months prior to screening.
Previous corneal transplant or clinically significant corneal dystrophy, e.g., Fuch's dystrophy (≥12 confluent guttae)
Unclear ocular media prevent visualization of the fundus or anterior chamber angle.
Uncontrolled systemic disease that in the opinion of the Investigator would put the subject's health at risk and/or prevent the subject from completing all study visits.
Current participation in another investigational drug or device clinical trial (which includes the fellow eye) within the past 30 calendar days.
Pregnant or nursing women; or women of childbearing age not using medically acceptable contraceptives.
Cataract surgery (if ≥ 2 years or screening)
YAG capsulotomy (if ≥ 60 days of screening)

What this trial measures

  • Mean Decrease in Intraocular Pressure (IOP) from BaselineBaseline to Month 3

    Mean IOP reduction from untreated baseline (T0) to 3 months following bilateral DSLT, averaged between both eyes at the two timepoints.